These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.
That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present value (the current value of potential future sales) of all the experimental drugs in biopharmaceutical companies' pipelines for which sales forecasts are available, then ranked them.
Biogen (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), AbbVie (NYSE: ABBV), and Celgene (NASDAQ: CELG) can each claim a pipeline candidate in the top five. Here's which drugs made the list and why they're worth so much -- even before they've made it to market.
Source: Fool.com
Johnson & Johnson Stock
€139.90
-0.100%
The stock is one of the favorites of our community with 32 Buy predictions and 1 Sell predictions.
With a target price of 196 € there is a positive potential of 40.1% for Johnson & Johnson compared to the current price of 139.9 €.
